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Firms’ intangible assets are becoming more and more relevant in the different areas within the financial discipline. Its 
management, its quantification and its valuation nowadays constitute one of the main challenges which economy and 
business try to face. Through this paper we will evaluate some models based on the real options theory in order to estimate 
the intangible assets value of certain firms, specifically I+D biotechnological firms projects. With this aim, and after deep 
research on biotechnological industry, we will establish the parameters regarding one model which can be considered as a 
quantitative valuation method that we apply to a sample of biotechnological European companies. The results obtained 







One of the most complex problems in the field of firms’ 
valuation is the value determination of high technology 
projects, and more specifically those dealing with 
biotechnological firms. Many of these firms haven’t got any 
benefit; however, they are listed in stock exchanges and 
keep a wide capitalization in capital markets. It is obvious 
that the usage of the classical discounted cash flow method 
is not easy; besides that, this use would lead us to results 
which would be quite different from the prices established 
in the markets. In the case of biotechnology, how to 
evaluate a patent is the main focus of interest from the 
economic point of view; another relevant aspect is how 
much investors must pay for such patent through the 
markets, a merger, an acquisition or another type of 
strategic agreement. In previous research1, we have 
explained some arguments which led us to the application 
of the so called “Real Options Method”.  Nevertheless, the 
most difficult point is the insertion of necessary and 
                                                 
1 Rubio Martín, G.(2004). 
  Lamothe, P., Rubio G. (2004). 
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accurate data or parameters in the models. We did so in the 
case of the Spanish biotechnological firm Zeltia, a case 
based on previous research by Kellogg and Charnes (2000) 
in which data from Myers and Howe (1997) were taken; 
moreover, this research showed some work carried out by 
Grawoski and Di Masi (1994), studies regarding the 
industrial behaviour in the 80’s. 
Through this paper we will develop some “average” 
parameters which must be considered as common to every 
medicine in its developing phase; we will also analyse latest 
research by Di Masi, Ron Hansen and Grawoski (2002) 
regarding this field dated at the end of the 90’s; then we 
will contrast that research with other recent studies and we 
will apply it to the development of a model based on 
different authors such as Schwartz (2001), Pindick (1993) 
and Trigeorggis (1996) as we will describe in the next 
paragraphs. Finally, we will prove its efficacy on a broad 
European technological firms center. 
The discovery of a new substance or active component with 
therapeutical capacity is the first part of this scientific 
research process and technological development (See figure 
1). Then a series of tests and trials must be carried out with 
the aim of guarantee the effectiveness and the reliability of 
the medicine to be marketed.  
 
1. - Preclinical phases: the active component is 
subjected to a complex battery of tests in vitro as 
well as to tests with animals in order to identify 
possible toxic effects and establish the 
pharmacological characteristics of the new 
substance.  
2. - Clinical phases: once the previous tests have 
been overcome, the promising products are 
exposed to a second process in which, at the same 
time, we can distinguish a group of phases 






                                                                                            
JOURNAL OF TECHNOLOGY MANAGEMENT & INNOVATION © UNIVERSIDAD DE TALCA 
 
Source: EFPIA 2003. 
 
According to the previous paragraphs, it is easy to 
determine that the innovation of a new medicine is a 
process whose features are uncertainty, risk and resources 
and time consumptions.  This process complexity is shown 
even in the first phases for the obtaining of the chemical 
compound which will constitute the basis for the next drug; 
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in fact, we can see how probability of a drug becoming 
commercialised is lower than 2% and, according to other 
research, even 0.02%.  Once the drug has reached the 
clinical phases, its success probability increases in a 
remarkable way. This process of scientific research requires 
a great number of financial and human resources which 
have considerable increased in the last twenty years. It is 
not unusual to talk about 12/13 years when referring to the 
period of time taking place from the obtaining of a new 
active component up to it is launched to the market, an 
aspect which leads to losses and to non-obtaining benefits 
during long periods of time.  
 
As a consequence of this situation, full of competitiveness, 
uncertainty and risk, we consider that it would be possible 
to set a “benchmark” which can be common to all 
components in their developing phase in order to be useful 
when evaluating biotechnological firms.  
 
ESTIMATION AND SIMULATION OF 
FREE CASH FLOWS: 
A  DRUG’S LIFE.  
 
In the same research quoted before, its authors, Di Masi, 
Ron Hansen y Grawoski (2002), show a return study, 
specifically dealing with free cash flows which _at the 
drug’s launching time_ are valued by deciles:  
 
Figure 2. Cash flows present values.  
 
Source: Grawoski, Vernon and Di Masi 2002. 
 
The test study shows a great concentration on sales, due to 
the fact, that only the three first deciles would cover the 
cost of necessary research and development in order to 
launch a product as figure 2 shows. So the levels of 
uncertainty and risk generating this kind of projects are 
higher than the ones in more traditional fields. 
 From this data we elaborate the “overage net present 
value” NPV at the time the product is launched: 
NPV=0,10*(2700+1000+733,33+433,33+233,33+133,33+6
6,66+33,33+16,65+0)=525 
We divide the cost by the number of periods in which it is 
generated (twenty years); then we obtain the annual cash 
flow “Co=26, 24” (mill$).    
Our model will show the flows projection according to the 
compound life following these premises: The patent 
expiration will take place twelve years after its launch. 
Sales, and subsequently cash flows, will have a rising 
progression up to the end of the 9th year.  The growth rate 
used is the historical rate in the field, as Grawoski, Vernon 
and Di Masi declare (2002); their research gives a 
profitability percentage of 11% from the usage of the 
CAPM and previous studies2. 
From the 23th quarter, a mean reversion process with an 
annual adjustment speed of 69,3147% will occur; this fact 
will imply that, at the beginning of the 7th year or the 28th 
quarter, the growth rate has reverted to a medium rate 
growth  estimated as 2%; this rate will remain up to the end 
of the 9th year3 
Later, a degrading process in the growth rate will take place 
and it will reach zero at the end of the 10th year by using an 
                                                 
2For other research, see Myers and Shyum-Sunder. (1993) and Myers and 
Howe. (1997). 
3Medium growth of the Euro Zone according to foresights by the Comisión 
of financial matters. 
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adjustment speed of 100%. During the 11th year, the sales 
growth rate will be zero, which will turn the process into a 
random trip.  
From the patent expiration moment, year 12th, basically 
due to the introduction of generics products, the decreasing 
percentage mean _according to some research_ will be 
31%, 28%, 20% and 20% respectively. In order to simulate 
the process, we have applied a average decreasing annual 
speed over the flow of 25% until the process is totally 
extinguished in the 20th year.   
 
 Figure 3. Sales by decil.  
 
              Source: Grawoski, Vernen and Di Masi 2002. 
  
From the previous data, we will analytically elaborate the cash flow generating process through Monte Carlo simulation for 
30.000 paths and quarterly periods following the stochastic functions below:  
1º- A Geometric Brownian motion, also means that the differences between both moments in time, t1 y t0 are represented by 
a normal distribution “dw”, in which σ is volatility (uncertainty about future movements in the underlying asset) and α  is 
the average annual rate of growth used by investors.  
CdwCdtdC σα +=  
 
 In the equation above we could use a “Risk Premium” associated with the dynamic generating process of the cash flow:  
( ) CdwCdtdC φηα +−=  
Assuming the proposal of a dynamic “Capital Asset Pricing Model” by Merton, we can determine a simple way of 
calculating the “Risk Premium” rate for the project:  
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Changes in the cash flow value.  
 
Source: own elaboration. 
 




nteCC σµ += ;   
)1,0(01 ntLnCLnC σµ +=− ; 





CLn σµ +=  
 
Where 
)2/1( 2* σαµ −=  . In order to develop the stochastic process, we need to determine the derivation of the prices 
logarithm by applying ITO’s lemma, whose verification is not included in the following research; this result leads us to the 
following formula:  
dwdt
C




Subsequently, we find the simulating equation of a Brownian geometric process in discrete time:  
))1,0()5,0(
01
2* tnteCC σσα +−= (1) 
ISSN: 0718-2724. 
31
J. Technol. Manag. Innov., 2006, Vol. 1, No. 2. 
 
(http://www.jotmi.org)   
2º- An Orstein-Ulemberck mean reversion process for the cash flow rate of growth generating process from the 7th year of 
commercialisation4 
dzdtd θαακα +−= )(1                              
 Implies that there is a reversion force over the variable α  towards a medium level α ,  according to the reversion speed 
1κ . Variable α  has a normal distribution with the following expression for its mean and for its variance: 
))exp(1()exp()0()( 11 ttkE κααα −−+−=  
 In the expected value, the mean is just a mid-point between the initial value and the long-term value. 
 1
2
1 2/*))2exp(1()( κσκα tVar −−=
In an average time, the movement of variable α  towards its mean will remain as the addition of the expected value and its 
volatility with a random component which is a normal (0,1)5: 
 
)1,0(2/))2exp(1())exp(1()exp( 11111 Ntttktt κκσκααα −−+−−+−= −  
 In order to adjust the process to the firm risk premium:6
)2();1,0(2/))2exp(1())exp(1)(/()exp( 111111 Ntttktt κκσκκβααα −−+−−−+−= −  
There is a relationship between the adjustment speed 1κ and the average life or the time which α takes to reach half of the 
way to get its long-term level α : 
κ/)2(LnH =  
3ª- A degrading process for the growth rate until it disappears implies that the flow would move once the adjustment was 
finished only according to its stochastic component7. 
dttd )(2ακα −=  
By integrating, we find its discrete version:  
 
(3) )exp(* 21 tktt −= −αα                                                                     
 4º- Another degrading process would imply the market definite exhaustion, considering that it is perfect, through the 
introduction of new and best products.  
 
dttCdC )(3κ−=  ; Its discrete time version:       
(4) )exp(* 31 tkCC tt −= −  
 
 
                                                 
4 Grabowski, Vernon and Dimaxi..(2002) 
5 Dixit and Pindyck.(1994) 
6 Schwartz. (2002). 
7 Lamothe and Aragón.(2002). 
ISSN: 0718-2724.                                                                                             
JOURNAL OF TECHNOLOGY MANAGEMENT & INNOVATION © UNIVERSIDAD DE TALCA 32
(http://www.jotmi.org)   
Figure 4. Cash flows simulation in Mat-Lab. 










Source: own elaboration.  
 
 
REST OF ESTIMATION OF THE FREE CAHS-FLOW’S PARAMETERS FOR EUROPEAN   
BIOTECHNOLOGICAL FIRMS’ CICLE LIFE. 
 
Volatilities and Betas in the market.  
Market volatilities and betas will be used for free cash flow simulation along the new drug’s commercial life. We have 
selected a representative group of european biotechnological firms whose volatility and beta parameters are shown in chart 
1: 
 
Chart 1. Market  Volatilities and Betas of our firms’ sample. 
 
  Volatility(Q)8 Beta Sources 
Elan  66,11% 1,62 Yahoo Finance 
Serono 32,30% 1,1 Volatility.com 
ARK Therapeutic 41,03% Nd focus.com 
Celltech 47,64% 0,71 Yahoo Finance 
Vernalis 150,62% 0,22 Yahoo Finance 
GPC Biotech 44,17% 0,89 Yahoo Finance 
Medigene AGN 44,30% 0,86 Yahoo Finance 
Nicox 72,03% 0,79 Yahoo Finance 
Zeltia 19,61% 0,77 Yahoo Finance 
Average 57,53% 0,87 Elab propia 






                                                 
8 Volatilities are provided according to annual terms. However, Yahoo Finance volatility is calculated on four-monthly data. It is calculated on monthly 
data within the website of financial analysis “Focus.com”. Results shown by “Volatility.com” correspond toa n implicit volatility over the ordinary price of 
a call option.  
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Chart 2. Volatilities for ten of the biggest biotechnological firms. Market data.  
 
 
  Volatility(Q) 
Amgen     26,47% 
Genentech     36,94% 
Serono     32,30% 
Biogen     37,27% 
Genzyme     36,96% 
Chiron     47,68% 
Medimune     30,76% 
Celltech group     47,64% 
Gilead Science     36,76% 
Averages     37,07% 
                 
  Source: Top Biophamaceutical companies report. 20039
Profits volatilities will be used to determine the costs evolution. Accounting rules dispersion in the financial information 
provided by the firms appearing in our sample does not let us extract volatility regarding research and development. 
Nevertheless, since these expenses are incorporated in the profit and loss account, variation and volatility of the account 
according to every firm are substitute indicators for the previous ones. 
 
Chart 3.  Profits  Volatilities.. 
 
  Currency  Profit 03 Pofit 02 Profit 01 Profit 00 Volatiliity 
Elan  (mill $) -535,40 -2362,3 268,9 -294,5   
Var Lg   148,44% -787,52% 633,40%   722% 
Serono (mill $) 389,96 320,78 316,7 301   
Var Lg   19,53% 1,28% 5,08%   10% 
ARK Therapeutic (mill L) -8,11 -5,72 -4     
Var Lg   -34,91% -35,77%     35% 
Celltech (mill L) -58,50 -54,8 -45,2 -426,2   
Var Lg   -6,53% -19,26% 224,38%   137% 
Vernalis (mill L) -34,25 -29,99 -53,33 -40,97   
Var Lg   -13,28% 57,56% -26,37%   45% 
GPC Biotech (mill €) -26,83 -32,94 -26,20     
Var Lg   20,52% -22,89%     31% 
Medigene AGN (mill $) VER -31,06 -38,87 -110,49 -9,26   
Var Lg   22,43% 104,47% -247,92%   184% 
Nicox (mill €) -19,48 -15,69 -11,52 -3,008   
Var Lg   -21,64% -30,89% -134,28%   63% 
Zeltia (mill €) 2,85 4,68 9,13 12,71   
Var Lg   -49,60% -66,83% -33,08%   17% 
Averages10           65% 
 
Source: own elaboration from the annual account of the firms.. 




10  Elan firm has been eliminated in the calculation of the average variation in our sample since this firm caused a huge distorsion. 
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Risk-Free rate.  
We will use this rate in order to discount cash flows and, later on, the I+D Cash-Cost flows differences counterfoil. We have 
applied a rate of 5% with the aim of determining the value of the project. Its estimation is taken from the euro denominate 
bond yield for ten years.  
 
Risk Premium. 
We have assumed a Risk Premium rate for the risky assets portfolio of 4,25% taking into account financial research about 
the European case.11
In the figure 4 we show the simulation evolution of the cash-flows across 30.000 paths with quaterly periods, incorporating 
reversion and exhaustion process.  
 
 
FUNCTION COST DESCRIPTION: SUCCESS AND DEVELOPMENT COST 
PROBABILITIES FOR THE PRODUCT. 
 
By the end of the 90’s (94-97 period), Grawoski, Vernon and Di Masi (2002) establish a cost of 480 million dollars, after 
taxes, including unsuccessful drugs cost (it is necessary to discover 5.000-10.000 molecules so that one of them can be 
launched) and capitalised to a rate of 11% at the drug launching moment. From this data, we will present an “out- pocket” 
expense chart which will not include failure probability or phase-to-phase capitalization. To do so, we will take Parexel 




Chart 6. Discovery and development process for the component.  
 
                                              Years             cost  % 
Basic research                           2.5                 4 
Discovery                                  3                   15 
Preclinical Development           1                   10 
Phase I                                       1.5                15 
Phase II                                      2                   22 
Phase III                                     2.5                31 
FDA review and approval         1.5                  3 
Total                                         14.0              100  
 Source: Parexel. 2001. 
 
We will distribute the cost among the different phases in order to elaborate the most realistic model:  
 
 
Chart 7. Cost assignment.  
 

























  12,87 
   51 
Σ 480 (mill$) 
Source: own elaboration and  Parexel 2001. 
                                                 
11 Vease Welch.(2001). 
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Launching Approval Phase III Phase II  Phase I Preclinical Discovery 
429 51 11,0051 87,6046 50,4594 29,4188 17,6690 18,9099 
Source: own elaboration . 
 
We know that probabilities are multiplicative12 ; for 
instance, if we have the average probabilities for a 
component and we want to establish its probability of 
reaching the market, we will follow this procedure:  
0,60*0,90*0,75*0,50*0,85*0,75= 0,1291; this means that it 
is necessary to discover 7,75 active molecules so that one of 
them can be commercialised: 1/0,1291=7,7459. If the cost 
for a compound in its discovery phase is over 76,57 million 
dollars, each compound will have a cost of 9,88 million 
dollars without taking into account unsuccessful 
probability. The lower the success probability we assign is, 
the higher the number of molecules which must enter one 
phase will be so that one of them can be launched (thus, the 
cost we will assign to an isolated compound will be lower).  
                                                 
12 The same process we are describing is developed in apendix “B” by 
Myers &Howe (1997) from data concerning success probabilities for 
certain compounds carried out by Di Masi (1991) for the pharmaceutical 
field. 
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 Chart 9. Success probabilities.  
 
 Success intermediate probabilities Success final probabilities 
R&D 60% 16% 
PRECLÍNICAL 90% 27% 
PHASE I 75% 30% 
PHASE II 50% 40% 
PHASE III 85%→90% 63%→ 81%13
FDA. FILING 75%→90% 75%→ 90% 
Source: Kellog & Charnes. 2000. Myers & Howe. 1997. 
 
                                                 
13 Myers & Howe probabilities (1997) are subsequently modified by Kellogg & Charnes (2000). At this point of the research we will set the original 
probabilities by the previous authors.  
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In previous analysis by the biotechnological spanish firm 
Zeltia, we considered costs and probabilities used in 
Kellogg & Charnes (2000); however, these authors took 
into account originary research by Di Masi (1991); this 
autor established probabilities only from the drug clinical 
phase I; that is the reason why previous probabilities are 
assumed by the models with no difficulty. An explanation 
to something with a poor scientific basis is found in Myers 
and Howe (1997): it makes no difference if a higher 
probability is used for the two first phases when we are 
rising the cost in a proportional way. Then, we must 
formulate the following question: if we can change costs 
while keeping the same proportion in probabilities. They 
seem not very realistic and they should be considered as a 
valuation distortion.  
In his latest research, Di Masi points at two relevant facts: 
Costs are increasing due to a higher number of open paths. 
Success costs and probabilities for the pharmaceutical and 
biotechnological fields tend to converge.  
In fact, Gosse (1996) declares that success probabilities for 
a biotechnological component in its preclinical phase 
extremely decrease at the end of the 80’s until they reach a 
percentage of only 10% compared to the 36% which Struck 
Marck (1994) establishes and the 27% by Myers & Howe 
(1997). These estimations coincide on later research about 
the pharmaceutical field since they establish lower 
probabilities: 
  
Chart 10.  Survival degree for compounds from 29 pharmaceutical firms. 
 
Start of stage                           Probability of reaching market % 
Preclinical development                                                     10.3 
Phase I                                                                                18.4 
Phase II                                                                               28.1 
Phase III                                                                              65.8 
FDA review & approval                                                    90.6 
      
 Source: Parexel. 2001. 
 
For this reason, under conservative criteria, we will compare both possible uses so that we can analyse whether our model 
can use higher probabilities (chart 11) with higher costs or it is necessary to adopt a more realistic point of view, including 
lower success probabilities and lower costs in a proportional way (chart 12).   
 
Chart 11. Costs and probabilities. 
 
 Discovery Preclinical Phase I  Phase II Phase III FDA approval 
Success 
probability. 
16% 27% 30% 40% 63% 75% 
Number of 
drugs.  
7,746 4,648 4,183 3,137 1,569 1,333 
Cost per 
approved drug14
18,90 17,67 29,42 50,46 87,60 11 
Cost per phase 
and drug. 
2,44 3,81 7,04 16,12 55,80 8,27 
 
Source: own elaboration from Kellogg and Charnes’ probabilities (2000); up to date according to costs evolution by  Di Masi et al. 2002. 
 
From the chart above, we obtained a total figure of 93,48 million dollars which, adding post-launching costs, makes 144,48 
million dollars. 
 
Chart  12 . Costs and probabilities.  
 




0,02% 10,3% 18,4% 28,1% 65,8% 90,6% 
Number of drugs.  500016 9,7 5,43 3,56 1,52 1,10 
Costper approved 18,90 17,67 29,42 50,46 87,60 11 
                                                 
14Di Masi .(2002) and Parexel. (2001). 
15 PHARMA Annual Survey. (2001). 
16 It implies that, from each 5000 molecules which have been discovered, only one will reach the market. 
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drug. 
Cost per phase 
and drug. 
0,0038 1,82 5,42 14,17 57,63 10 
 
Source: own elaboration from Parexel 2002 and Di Masi et al. 2002. probabilities. 
 
However, according to data in chart 12, they reach a figure of 89,04 million dollars which, added to post-launching research 
costs, makes a total figure of “out-pocket” expenses of  140,04 million dollars. 
In the next paragraphs we will show the stochastic simulation process through 30.000 paths, whose explanation is described 
as follows: we assumed the same widespread process which was previously developed by Pindyck17 establishing two 
sources of uncertainty according to costs. The first uncertainty source will be known only after the phase is carried out, 
since expenses will change as a consequence of this fact; we cannot know that before and this is the reason why the 
expected value of the costs increases. The second uncertainty can be known before initiating the phase; this fact involves an 
abandonment Option; that is to say, this phase will start only if costs have been reduced or have not increased so much as 
for the project to be profitable; if it was not this way, it would be neglected. The first uncertainty (technical uncertainty), is 
related to the amount of time, effort and materials which would be necessary in order to finish the project because of 
previous unexpected problems in its implementation. The second uncertainty (the one regarding costs prices for the raw 
materials which must be used) takes place because of changes in the State regulation and also is due to general economic 
framework:  
 ,  dzKIgIdtdk ),(+−=
Where I, is the investment rate in every period, dz is a Wienner process which may or may not be related to finance and 
market prices. The above equation implies that the costs decrease gradually when the investment is being carried out; 
however, there is also a stochastic component due to technical factors or costs matters.  
The author assumes that there is a maximum type of investment K; F(K)= F(K;V;k) ; the investment opportunity value 
fulfills:  














dtetIVeEkF )(max)( 0 ,  
He sets the costs structure as follows:  
αβ )/(),( KIKKIg = ,  with 2
10 ≤≤α  
Pindyck restrict the analysis to 0=α y 2
1
=α , which corresponds to both types of uncertainty. 
The first case corresponds to variations in the price of costs; in this case the instant variance of dK/K  is constant e 
independent from  I, K; it may fluctuate even if the investment is not carried out: 
KKIg γ=),(  
The second case deals with technical uncertainty. K may change only if an investment is initiated; the total costs will only 
be known at the end of such investment; moreover, variance dk/k increases lineally according to the increment of ratio I/K: 
2/1)(),( IKKIg β=   
Subsequently, this is K evolution:  
KdwdzIKIdtdk γβ ++−= 2/1)(  
Where dz and dw are two Wienner processes; the first one is not correlated with the market, but the second one is. To sum 
up, the previous equation combines uncertainty about the degree of effort required to complete the project over the costs 
price and the time it will take.  
Schwartz only includes technical uncertainty and not uncertainty derived from changes in the costs evolution:  
                                                 
17 Robert. S. Pindyck. (1997). 
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dzIKIdtdk 2/1)(σ+−=   
 In a discrete time, this would be the development of the equation above:  
1
2/12/1 )()()()( εσ tIKtItKttK ∆+∆−=∆+  (5) 
Besides this, during the simulation process we have rejected values in the costs function which may be considered 
negatively.  
Now we will show the result of the costs function simulation. We find a lower exhaustion slope than in the case of 
nutraceutical products18. This is due to the fact that they keep a very high I+D costs in the post-launching phase in the 
parameters that have been used, which implies a lower exhaustion in the costs function19. 
 
 
 Figure 5. Costs function.   










Source: own elaboration.  
 
INVESTMENT OPTION AND ABANDONMENT OPTION VALUES. 
 
 The Investment Option in a moment in time before it is finished the investment is F(C,K,t); it depends on the cash flows 
which may be accrued, the remaining costs in order to finish the project and how long it will take until its end. This value 
must fulfils the following differential equation based on previously developed research Pindyck20 with four differences: 
Schwartz introduces the “risk premium”, a correlation between I+D expenses and cash flows, which the previous author did 
not notice; he does not take into account costs uncertainty and introduces unsuccessful possibility for the Project through the 








⎡ −+−+−∗+++ IFrFtIFkCFcFckIKCFkkIKFccCMax λαφσρσφ With the 
following limited condition:  
),(),0,( tCVtCF =  
That is to say, when the investment process is finished, the project value will be that of the outstanding cash flows, where 
λ is the Poisson probability, per time unit, for the project to be unsuccessful.  
                                                 
18 Lamothe,P., Rubio G. (2004). 
19 See Di Masi et al (2002). 
20 Robert. S. Pindyck. (1997). 
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The limited condition difficult the process in the fact that we do not know the investment project length; thus, it turns into a 
new random variable and makes the differential equation unsolved by traditional numerical methods.   
The author shows the way the equation must be solved following a simulation system with two simplifying conditions:  
- The investment strategy takes two probable extremes: investing with the highest possible rate, or not investing. 
This policy is ideal only when cash flows and I+D expenses are not correlated with each other.  
- Once the project is abandoned, it will not start again if the cash flows do not improve in the future: since there is no 
expiration date for the patent, all this neglecting and restarting process may be excessively expensive.  
Without any uncertainty, the project value would be like this:  
 









• A solution for the Process.  
Since there is not an analytical solution, the author sets the way in which the process can be solved by a Monte Carlo 
simulation, determining the abandonment options as discreet points in the model. To do so, we define two phases:   
The “Backward” phase (from front to back). Once the cash flows matrix has been determined according to the formulas (1), 
(2), (3) y (4) applying a “Forward” strategy from the zero moment onwards, we will carry out the simulation from the last 
period backwards, obtaining the accumulated and up to date cash flows at the launching moment of the product for every 
path; so, if the I+D phase had finished and the project had not been left, the project value would have been as follows:  
tjiCjiWtrjiW ∆++∆−= ),()1,()exp(),(  
Afterwards, we simulate the outstanding costs matrix for I+D according to formula (5) and we calculate the “Project 
Value” counterfoil again W(i,j) as the rest between the previous ones for each path and time.  See how the path value 
increases when the time project goes by and the outstanding cost is lower. Although some paths take negative values, their 
number becomes lower when the project is closer to its ending and its launching to the market and, as a consequence, the 
number of paths which must be left is lower and the project value becomes higher.  
 
Figure 6. Values function for the project.  











 Source: own elaboration.  
 
From this point we will develop the “Backward” strategy once more, calculating the Project values according to the 
“Abandonment Option” by Schwartz (2001). We will determine the ideal abandonment strategy through a Montecarlo 
“Least-Square” process which will be described later, following the conditions below until we arrive at the zero moment 
with every possible path and time:   
1- The Project will be left if its expected value in the next period (a value which is obtained by the Longstaff-Schwartz 
algorithm) is lower than the investment required in this period. In the case the project is abandoned in the I+D phase, the 
project value will be zero: 
                 
 0),(ˆ),( >∆−= tIjiWji W
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As if it was a European Option, we will “regress” the discounted value in every period from vectors K(i,j) y C(i,j) with the 
value in the previous period, using nine polynomials as regressors, from the variables and  their lineal and square 
combinations; so we will get the best lineal and non-biased estimator for the project expected value,  . ),(ˆ jiW
Let us suppose an stochastic process as a simple example in order to evaluate a Buying Option where Y is the Project value 
variable at a “t” moment from the rest between the accounting year price 1 and the cash flows in that period  
(0,80;1,05;1,019;1,22) and X (1,10;0,80;1,09;1,05) represents the cash flows in the previous period. The process will 
maximize options value within the money: Project value > Exercise price, so we optimize the Y variable according to its 








Paths    X  Y E[Y/X] I*dt Option 
1 1,10      0 -0,0144 0,10 Neglecting  
2 0      --------  -------- 0,10 Neglecting 
3 1,09  0,019*e-0,05 0,0366 0,10 Neglecting 
4 1,05  0,22*e-0,05 0,2057 0,10 Continuing 
Source: own elaboration. 
  
In order to determine that the Project must not be abandoned, and as we said before, E(Y/X) must be higher than the 
outstanding investment I*dt in a certain period. When we neglect in certain points within the product cycle, we are 
introducing a “jumping” system similar to that one taking place in a Poisson distribution.  
 
Figure 7. 












Source: own elaboration. . 
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2- This is how the positive values resulting from the application of this recession, which will described later, are as follows:     
  ),(ˆ jiW
    ))1,(ˆ)(exp(),( jIjiWrjiW −++−= λ
       
 In order to finish the simulation process, we will establish the average value for every possible different path, and also its 
present value, by applying the success probability that the product may reach the market added to the discount rate 
according to data from charts 11 an 12 and following a Poisson distribution. For instance, we will apply a success 
probability percentage of 16%, which implies an abandonment probability  of  84% (1-0.16) for a product in its discovery 
phase.    
                







We extract the up to date costs in previous periods ( ) from every value resulting from the counterfoil difference between 
the outstanding cash flow and cost. These amounts represent a “financial buffer” that we demand of the investment since 
this industry nature constantly leads to the reinvestment of one part of the obtained funds. If it was not able, the firm being 
evaluated would not easily survive in a medium or a long term.  
jI
 
    Figure 8. Graphic representing the project present values.  










           Source: own elaboration.  
 
VARIABLES CORRELATION.  
 
As a hypothesis for the model, we have established that the 
cash flows and the costs are not correlated. In the following 
sensitivity analysis we will see what would happen if, as 
Schwartz (2001) suggests21, the correlation between both 
variables was very weak and had a negative sign, 
specifically  -0,01%. 
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21 Regarding variables correlation also see  Shimko. (1992) and Trigeorgis. 
(1996). 
In Wienner process for the correlation of two variables 
which follow both stochastic processes, it would be enough 
if their volatilities or uncertainty sources22, were correlated. 
So, this fact must be fulfilled:  
ρ=31 * zz dd  
Where  and  are two normal distributions (0,1). 1Z 3Z
                                                 




(http://www.jotmi.org)   
In order to correlate both distributions, we have provided 
the bivariable distribution  with some content starting 







































Which implies that:  213 ZZZ += ρ  




and a normal one  (0,1) and  a correlation rate regarding  
, 
3Z
1Z ρ . 






2 =−+=+= ρρσσρσ ZZZ
 
and its arithmetic mean is zero.     0)( 3 =ZE
 
SIMULATION RESULTS. ANALYSIS.  
 
 In the next paragraphs we will present the analysis results 
for a compound in its discovery phase considering different 
probabilities and volatilities. 
  
Chart 14. .Products in their discovery phases.  
 
Different probabilities VALUES 
P*=0,16 (Kellogg &Charnes)  
%37=σ   12,47 
%57=σ   82,07 
P*=0,02 (Paraxel,Di Masi)  
%37=σ  -6,98 
%57=σ  29,66 
P*=0,0002 (Paraxel)  
%37=σ  -39,08 
%57=σ  -12,93  
 Source: own elaboration. . 
 
We find that, for probabilities under 2%, the project value 
is always negative. In order to compare the data which has 
been obtained applying this model and the one which has 
been calculated following other methods, we take the same 
success probability previously used (16%) for a product in 
its discovery phase with a volatility of 37% and we get a 
similar value for a product in its discovery phase (12,47 
mill) as in previous research. So we are close to the “basic” 
solution established by Schwartz (2001). Nevertheless, 
these solutions are not completely accurate from our point 
of view. 
Probabilities over 2%, for a compound in its discovery 
phase are not real. Probabilities for biotechnological 
products have gradually converged with probabilities for 
the most conventional or chemical compounds, which are 
under 2% or even 0,02%, according to different research. In 
our opinion, theories which have been applied to use higher 
probabilities by the quoted authors do not seem to be very 
convincing.  
 
Myers & Howe start from the presupposition that 
probabilities and costs are directly proportional; they think 
that we can increase them without any problem, also 
increasing costs in a proportional way. However, this fact is 
not possible, at least in our model, since in this case the 
usage of lower probabilities with lower proportional costs 
must be the same as the usage of higher probabilities and 
higher costs, and this does not happen. Valuation changes 
automatically from positive values to negative ones starting 
from probabilities which are lower than  2%. 
 
 Schwartz (2002) makes a distinction between 
“unsuccessful financial probability” and “unsuccessful 
technical probability”. With regards to the usage of higher 
probabilities than the ones in the market, he believes that 
the “abandonment option” (which was introduced in the 
model by the Longstaff-Schwartz algorithm) means the 
origin of financial failure; thus, there are only technical 
unsuccessful probabilities, which represent 50% of the total 
possible unsuccessful. Nevertheless, the effects deriving 
from the application of the neglecting option are not close 
to 50% of the global unsuccess/success probability effect 
through a Poisson distribution: we consider that this fact is 
not replaceable.  
To sum up, we think that the usage of these probabilities 
(which are over the real ones) would only be recommended 
when a successful capacity for these products is 
presupposed after proving their efficiency and their new 
action mechanisms from the point of view of medical 
results, which would lead to financial results over the 
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average. However, we cannot forget that, when we apply 
probabilities over the average,  we are overweighting the 
project value in a way.  
In this case, a possible solution would be the evaluation of 
only one part; a percentage from the products in their 
discovery phase. For instance, in the case of Zeltia, which 
owns a really important portfolio of compounds in their 
discovery phase, 500 molecules, which have proved to be 
active in vitro against different types of cancer, we should 
only value 10%, so we would get final probabilities under 
2%. 
 
Now we will present a sensitivity analysis according to 




















Risk  Premium VALUES 
5%  5,23 
4,25% 12,47 
3% 22,03 
Rate of growth VALUES 
10% 7,98 
11% 12,47 
12% 13,81  
Source: own elaboration.  
 
Finally, we present the model results for the different phases in a drug’s development through the application of different 

















Chart  16. 
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PRODUCT IN ITS PRECLINICAL PHASE  VALOR 
P=27% %37=σ    43,19 
P=27% %57=σ  133,14 
P=10,3% %37=σ    14,23 
P=10,3% %57=σ    77,79 
PRODUCT IN ITS CLÍNICAL PHASE I  VALOR 
P=30% %37=σ    55,76 
P=30% %57=σ  187,31 
P=18,4% %37=σ    34,5 
P=18,4% %57=σ  140,53 
PRODUCT IN ITS CLÍNICAL PHASE II  VALOR 
P=40% %37=σ     87,04 
P=40% %57=σ   267,17 
P=28,1% %37=σ     66,88 
P=28,1% %57=σ   219,62 
PRODUCT IN ITS CLÍNICAL PHASE III  VALOR 
P=63% %37=σ   126,43                 (146,03; P=81%) 
P=63% %57=σ   360,95                 ( 426,65; P=81%)               
P=65,8% %37=σ   126,99 
P=65,8% %57=σ   369,33 
PRODUCT IN ITS APPROVAL PHASE  VALOR 
P=75% %37=σ    203,09                   
P=75% %57=σ    518,44              
P=90,6% %37=σ    220,14 
P=90,6% %57=σ    565,47 
Source: own elaboration.  
 
 
APPLICATION OF THE MODEL TO A 
SAMPLE OF EUROPEAN 
BIOTECHNOLOGICAL FIRMS. A 
COMPARISON TO THEIR MARKET 
VALUES.  
 
Compounds values in their different research phases change 
outstandingly according to the probabilities and volatilities 
that have been used; to give a more specific explanation, for 
a certain probability and different volatilities, we see how 
values multiply by 2,5 and 3 times, obtaining a wide range 
of values and proving the extremely high sensitivity of the 
model when facing cash flows volatility changes. 
These firms may really work with quite wide ranges 
according to the diverse probabilities and volatilities used 
as parameters. This is the reason why we establish a 
confidence interval for each one and, along this interval, 
values will quote according to the parameters that investors 
weight at every moment. However, it is necessary to 
consider folowing points:  
Regarding the analysis of the used volatilities, it is 
important to say that the mean referring to the ten most 
relevant biotechnological firms (all of them quoting in 
Nasdaq) is 37% (see chart 2), whereas our firms volatilities 
(see chart 1), firms that quote in European markets, is 57%. 
This data may mean the effects of a less efficient european 
market in the resources assignment comparing it to the 
american market. In Europe, the markets patchwork where 
these firms quote, the national disparity concerning the 
different rules which are applied up to this moment, 
referring to the accounting representation of research and 
development expenses, and the lack of investors and 
analysts specialized in these areas, are some of the many 
factors which have contributed to the existence of a more 
irrational and rougher movement of prices if we compare it 
to the one occurring in the american markets; this fact 
causes the appearance of different volatilities in both 
samples.  
 
Subsequently, there is a type of volatility which can be 
called “destructive”, a volatility that, in our opinion, creates 
a paradox concerning values. Compounds values increase 
and, however, this may be due to irrational movements 
(even with a decreasing feature), with a relevant tendency 
towards instability.  
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In order to determine a “parameterized” confidence 
interval, we will set two ranges: firstly, the lower one is 
calculated by using higher probabilities from Kellogg and 
Chames research and including average volatilities 
belonging to firms quoting in the American market; 
secondly, the higher range, including lower probabilities as 
in Parexel research and, simultaneously, containing higher 
volatilities from the firms in our sample research.   
The firms we have selected fulfil two common 
characteristics: the first one is that all of them are 
biotechnological firm specialized in drugs production, firms 
which assure new action solutions in the healing of illnesses 
such as cancer, alzheimer or multiple sclerosis; the second 
characteristic is that every firm quotes in “new stocks 
national markets” in a european level, more specifically in 
the Tech Market (London), where ARK. Therapeutic, 
Celltech and Vernalis also quote (firms which are selected 
in our research); the Neuer Market in Frankfurt, for GPC 
Biotech and Medigene AG; the  Nouveau Marché in Paris, 
where the french firm Nicox quotes, or the New Spanish 
Market, with the spanish firm Zeltia. Other european 
industries which are not provided with a nacional market to 
do so, quote in Nasdaq, as it happens to the irish firm Elan, 
or the swiss one, Serono 
To illustrate these datas, we will show a resume of these 





Chart 17. ZELTIA. (MILL €). 
 
 Fase Desc. Fase Preclín. Fase I. Fase II. Fase III. Fase registro. 
 500 (10%) 7 1 223 1 0 
Rango 
inferior. 
Vu 12,47 Vu   43,19 Vu  55,76 Vu  87,04 Vu 146,03 Vu 220,14 
Total. 623,5 302,33 55,76 174,08 126,43 0 
     ∑ totales  1282,1 
Rango 
superior. 
0 Vu  77,79 Vu 140,53 Vu 219,67 Vu 369,33 Vu 565,47  
Total. 0 544,53 140,53 439,34 369 0 
     ∑ totales  1493,4 
 
Valor Opción rango bajo. 1282,1 
Valor Opción rango alto. 1493,4 
Gordon.  140,7324
Nº de acciones. 200,7 
Valor min/Valor max por tit. (3,98)25/7,08/8,1426
 
Cotización 08/10/2004 5,60 Bien valorada. ⇒
 
The chart below resumes the final situation of our firms group according to the results obtained in our evaluation. The next 
one includes some interest indicators which analysts and investors should take into consideration when evaluating this kind 







Chart 18.Data resume.  
                                                 
23 Según datos proporcionados por la propia compañía el compuesto Kahalalide F valorado anteriormente en fase clínica I ha pasado a fase II para 
determinadas aplicaciones. 












= −−eV ;      
25 Si no sumásemos el valor de la cartera de compuestos en fase de descubrimiento. 
26 Si hubiésemos conservado la valoración por fundamentales de la compañía del capítulo 5 y mantenido el número de acciones, la valoración del rango 
bajo sería muy parecida para ambos modelos.  
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Firms Evaluation  
(€) 





Elan (3,72)-3,85-5,80 390,45/ 8.472 21,7 Overvalued 
Serono 374,78-505,21 22,7/ 11.372,7 501 Well valued 
ARK Therapeutics 2,50-7,71 110,63/ 132,756 1,20 Undervalued 
Celltech 3,86-6,70 278,46/ 2.302,86 8,27 Overvalued 
Vernalis 1,58-3,82 319,23/ 392,65 1,23 Well valued 
GPC Biotech (8,12)-11,60-20,94 28,62/ 315,11 11,01 Well valued 
Medigene AG 41,11-88,04 13,47/ 99,543  7,39 Undervalued 
Nicox 22,70-55,82 32,15/ 123,777  3,85 Undervalued 
Zeltia (3,98)-7,08-8,14 200,7/ 1123,92 5,60 Well valued  
Source: own elaboration.  
 
After analysing our research, we conclude by confirming 
that the values obtained through the parameterized model 
constitute “reasonable prices” for these firms which may 
let their usage for firms evaluation and biotechnological 
projects. Nevertheless, it is necessary to consider the 
following points:  
Due to the uncertainty and the risk that these firms 
incorporate to their investment projects because of possible 
and unpredictable changes in their business’ evolution, we 
can only determine a confidence interval for them. The 
companies’ prices should move along the interval for 
certain compound portfolio information according to some 
factors weighted by investors at any moment. Out of this 
confidence interval which we have set for every value, the 
firm would be undervalued or overvalued.   
According to the results that we have obtained, we can 
establish three ranges concerning firms:  
Well valued firms: companies whose price moves along the 
values range shown by our model. These firms are Serono, 
Vernalis, GPC Biotech and Zeltia. 
 
 
  Figure 9.Comparison of theorical values and market prices for analyzed firms. 
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Source: own elaboration. 
 
 
Overvalued firms according to the models in the dates and 
from data analysed by Elan and Celltech: in the case of 
Celltech, this overvalued result was due to a “control 
premium” which was paid by UBD in order to buy the 
company in 2004, more specifically, when the agreement 
was announced, the shares increased 26%. Without this 
increase, the firm prices would have been situated within 
the trust interval determined for our evaluation. Elan’s case 
is different: it seems that investors are betting on their drugs 
to become “block-buster” products whose sales and cash 
flows generation are situated in the sales higher range, 
whereas our model considers a mathematic expectation or 
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Figure 10.Comparison of theorical values and market prices for analyzed firms. 
                                                                                            
JOURNAL OF TECHNOLOGY MANAGEMENT & INNOVATION © UNIVERSIDAD DE TALCA 
es that, it is important to state that these three 
companies do not keep or have broken strategic agreements 
dealing with their products’ development, which leads us to 
conclude by saying that investors penalize or reward this 
 
Source: own elaboration.  
 
Undervalued firms such as ARK Therapeutics, Medigene 
AG and Nicox: firstly, it is relevant to say that stock market 
capitalization of the firms which constitute our sample is 
really diverse. The model presents a bias for those which 
have lower capitalization rates, especially Medigene AG 
and Nicox. It is a control or liquidity premium which can be 
found in these firms with a low number of issues and poor 
capitalizations. Subsequently, new shares issues and  capital 
expansion in these companies (as a possible solution to 
defray their research costs) may produce a comparative 
advantage over the rest of firms and not a disadvantage, 
always carrying out this procedure within some logical 
limits according to their needs and to the compounds they 
may develop.  
 
Figure 11.Comparison of theorical values and market prices for analyzed firms. 
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kind of facts which, from a quantitative point of view, are 
difficult to consider in our model. In fact, Nicox kept 
product development agreements with Axcan Farma, Bio 
polis and Astra Zeneca (its agreement with the later firms 
was broken in September and nowadays its issues quote 
65% under precedent prices. Medigene AG also broke its 
agreement with Aventis in 2004 (an agreement dealing with 
an anticancerous vaccine); this fact had a negative influence 
on its price. Medigene AG keeps another agreement with 
the Japanese firm Yamanouchi, but about 
commercialization and not of product development.  
Finally, ARK Therapeutics did not keep any collaboration 
agreement with any firm by the time of this research; 
however, it collaborates with other companies, such as 
“Crucell”, in the development of a new compound carried 
out by Crucell, a new component dealing with gene therapy 
(PER C6 TM, in November, 2000). Nevertheless, ARK 




Chart 19. Strategic indicators.  
 
 Firms Liquid assets 
 state.  
1st week 2004. 
(mill UM) 
Drugs in the market. Latest drug’s most 
advanced phase. 
Strategic agreements 
dealing with drug 
development.  
Elan   915,8   ($) 2 Launching phase. Biogen Idec. 
Serono 2383,05 ($) 8 Launching phase. Several 
ARK therapeutics   53,73 (L) 1(year 2004) Phase II  
Celltech 155 (L)31/12/03 6727 Phase III UCP28
Vernalis   24,21(L) 1 (year 2003) Phase III29 Biogen Idec, Roche, 
Serono. 
GPC Biotech   74,75 (€) None Phase III Altana. 
Medigene AG   32,81 (€) 1 (year 2003) Phase III  
Nicox   40,09(€) 31/12/03 None Phase III  
Zeltia 114,44 (€) None Phase III Ortho Biotech. 





                                                 
27 In spite of counting on a great number of products, the majority of them deal with chemistry and none of them has got a high rate of sales.  
28 It has been taken over by this dutch group in august 2004. 
29 It is the same drug which was approved (Frvatriptan) for others of its applications. 
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All these indicators (added to other aspects such as their 
cash-flows state, the presupposition that they have not 
launched any product to the market and the years up to their 
first drug launching) are data which should be a part of a 
strategic indicator in a wider study about this field.  
According to our research, we assert that the values shown 
by the parameterized model constitute “reasonable prices” 
for these firms which might let their usage in the 
management of an investment portfolio of biotechnological 
companies. However, due to the sensitivity in the models 
held to changes, it is necessary to estimate “spreads” or 
confidence intervals to the firms’ valuations; these intervals 
will exist during a certain temporal frame in which prices 
should move along that interval according to the weighting 
of one or the other factor or parameter by the analysts or the 
investors. Moreover, to keep the models in good working 
order, it is necessary to count on the most appropriate 
parameters; by doing so, we give relevance to the fact of 
establishing generally accepted criteria, since nowadays 
there are important discrepancies among the quoted 
authors, especially concerning probabilities application and 
volatilities.  
To end this research, it is necessary that the manager 
evaluates the behaviour of two factors playing an important 
rule in this kind of investments:  diversification and time. 
These investments imply an extremely high level of risk; 
the probability for a drug to be rejected is very high; many 
of these companies, especially the ones searching for 
“biotechnological” products, will never get any benefit and 
they will disappear. However, the action mechanisms that 
these new drugs have are so original that success in one of 
these firms may fully reward the investor who has 
participated in a well diversified portfolio. Regarding time, 
the maturity cycle for a compound is very long; this is the 
reason why the investment dealing with biotechnology 
should have a temporal horizon over five years, or even ten 
years, since this investment yield may only be valued in a 
long term.  
Anyway, we have verified that models based on real 
options seem to show “reasonable” values as far as its 
proximity to the prices of biotechnological firms in the 
market. In this research, as in many others, it seems that 
these “theoretical” financial models do not present very 
distant results to the prices of “reality” in the markets, 
including the necessary parameters which provide the 
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